Skip to main content
Premium Trial:

Request an Annual Quote

WHO Expands Prequalification Assessment for TB Molecular Test Developers

NEW YORK – The World Health Organization on Tuesday expanded an invitation for tuberculosis molecular diagnostic prequalification assessment to include manufacturers of qualitative assays. The eligibility expansion will become effective on Sept. 22, 2022.

Prequalification of in vitro diagnostic medical devices involves a comprehensive quality assessment of products through a standardized procedure, WHO said in a statement. The assessment is coordinated through the WHO Prequalification Unit and focuses on IVDs for priority diseases and their suitability for use in resource-limited settings.

In a document, the WHO invited manufacturers of in vitro diagnostic medical devices used for the qualitative detection of Mycobacterium tuberculosis complex DNA and mutations associated with drug-resistant tuberculosis to send a pre-submission form. The WHO will also hold a virtual workshop to describe the application process on Sept. 21.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.